Literature DB >> 7998792

The dissemination of multiple sclerosis: a Viking saga? A historical essay.

C M Poser1.   

Abstract

The highest prevalence rates for multiple sclerosis are found in Iceland, Scandinavia, the British Isles, and the countries settled by their inhabitants and their descendants, that is, the United States, Canada, Australia, and New Zealand. This suggests that the Vikings may have been instrumental in disseminating the genetic susceptibility to the disease in those areas as well as in other parts of the world. The Vikings raided in most European countries and settled in Normandy and in Sicily and southern Italy. They engaged in trade with the Arabs along the river routes to the Caucasus and to the Black and Caspian Seas and penetrated into Persia, India, and probably China. They also migrated to the East and established the Russian state. Under the name Varangians, they became part of the Byzantine army and were active in all of the military activities of the Byzantine Empire. They participated in the Crusades. Russians, many of Scandinavian origin, also constituted a regiment of the Mongol army and roamed throughout that empire as well. The custom of capturing and keeping or selling women and children, which was widespread in the early Middle Ages, as well as the flourishing slave trade in men, were important factors in this genetic dissemination.

Entities:  

Mesh:

Year:  1994        PMID: 7998792     DOI: 10.1002/ana.410360810

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland.

Authors:  Christopher McGuigan; Ciaran Dunne; John Crowley; Richard Hagan; Genevieve Rooney; Eimear Lawlor; Michael Hutchinson
Journal:  J Neurol       Date:  2005-09-16       Impact factor: 4.849

Review 2.  Genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

3.  The genetic aspects of multiple sclerosis.

Authors:  Stephen Sawcer
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

4.  FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis.

Authors:  Patrick K A Kearns; Sarah J Martin; Jessie Chang; Rozanna Meijboom; Elizabeth N York; Yingdi Chen; Christine Weaver; Amy Stenson; Katarzyna Hafezi; Stacey Thomson; Elizabeth Freyer; Lee Murphy; Adil Harroud; Peter Foley; David Hunt; Margaret McLeod; Jonathon O'Riordan; F J Carod-Artal; Niall J J MacDougall; Sergio E Baranzini; Adam D Waldman; Peter Connick; Siddharthan Chandran
Journal:  BMJ Open       Date:  2022-06-29       Impact factor: 3.006

5.  The role of infections in the pathogenesis and course of multiple sclerosis.

Authors:  Siddharama Pawate; Subramaniam Sriram
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

Review 6.  Prevalence of multiple sclerosis in Latin America and its relationship with European migration.

Authors:  Edgar Correa; Víctor Paredes; Braulio Martínez
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-09-02

Review 7.  State-of-the-Art Review: Demyelinating Diseases in Indonesia.

Authors:  Hana Larassati; Riwanti Estiasari; Reyhan E Yunus; Paul M Parizel
Journal:  Mult Scler Int       Date:  2021-06-23

8.  Association of urodynamic findings in new onset multiple sclerosis with subsequent occurrence of urinary symptoms and acute episode of disease in females.

Authors:  Farhad Tadayyon; Masoud Etemadifar; Hussein Bzeih; Mahtab Zargham; Kia Nouri-Mahdavi; Mojtaba Akbari; Borna Tadayyon
Journal:  J Res Med Sci       Date:  2012-04       Impact factor: 1.852

9.  Geographical and seasonal correlation of multiple sclerosis to sporadic schizophrenia.

Authors:  Markus Fritzsche
Journal:  Int J Health Geogr       Date:  2002-12-20       Impact factor: 3.918

Review 10.  Disseminated encephalomyelitis in children.

Authors:  Silvia N Tenembaum
Journal:  Clin Neurol Neurosurg       Date:  2008-02-12       Impact factor: 1.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.